City Therapeutics, Inc. (NASDAQ:CTY – Get Free Report) Director Robert Nelsen purchased 170,000 shares of the firm’s stock in a transaction on Monday, October 19th. The stock was bought at an average price of $18.00 per share, with a total value of $3,060,000.00. Following the acquisition, the director owned 13,692,507 shares in the company, valued at $246,465,126. This trade represents a 1.26% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
City Therapeutics Stock Down 4.2%
NASDAQ:CTY traded down $0.94 during trading hours on Monday, hitting $21.46. The stock had a trading volume of 302,365 shares. City Therapeutics, Inc. has a 1-year low of $20.50 and a 1-year high of $23.88.
About City Therapeutics
See Also
- Five stocks we like better than City Therapeutics
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
Receive News & Ratings for City Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for City Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
